Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 56, Issue 5, 2015, Pages 1379-1384

  Roy Moulik, Nirmalya ^a   Kumar, Archana ^a   Agrawal, Suraksha ^b   Awasthi, Shally ^a   Mahdi, Abbas Ali ^a   Kumar, Ashutosh ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Childhood ALL; Folate; Induction deaths; MTHFR

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ASPARAGINASE; DAUNORUBICIN; FOLIC ACID; METHOTREXATE; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVERSE OUTCOME; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CHILD; CYTOPENIA; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEBRILE NEUTROPENIA; FEMALE; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; GENOTYPE; HEPATITIS; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; NEUTROPHIL COUNT; PANCREATITIS; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TRANSFUSION; ADVERSE EFFECTS; ALLELE; BLOOD; GENETICS; PHARMACOGENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; TREATMENT OUTCOME;

ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLIC ACID; GENOTYPE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PHARMACOGENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 84932097004     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.947608     Document Type: Article

References (34)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
2. Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet 2003;362:706-708.
3. Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2004;291:2471-2475.
4. Asim M, Zaidi A, Ghafoor T, et al. Death analysis of childhood acute lymphoblastic leukaemia; experience at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan. J Pak Med Assoc 2011;61:666-670.
5. H a f z MG, Mannan MA. Nutritional status at initial presentation in childhood acute lymphoblastic leukemia and its Effect on induction of remission. Mymensingh Med J 2008; 17(2 Suppl.): S46-S51.
6. Bauer J, Jürgens H, Frühwald MC. Important aspects of nutrition in children with cancer. Adv Nutr 2011; 2: 67-77.
7. Sadananda Adiga MN, Chandy S, Ramaswamy G, et al. Homocysteine, vitamin B12 and folate status in pediatric acute lymphoblastic leukemia. Indian J Pediatr 2008; 75: 235-238.
8. Robien K. Folate during antifolate chemotherapy: what we know..and do not know. Nutr Clin Pract 2005;20:411-422.
9. Branda RF, Nigels E, Lafayette AR, et al. Nutritional folate status inf uences the ef cacy and toxicity of chemotherapy in rats. Blood 1998;92:2471-2476.
10. Alati T, Worzalla JF, Shih C, et al. Augmentation of the therapeutic activity of lometrexol-(6-R)5, 10-dideazatetrahydrofolate-by oral folic acid. Cancer Res 1996; 56: 2331-2335.
11. Kawakita D, Matsuo K, Sato F, et al. Association between dietary folate intake and clinical outcome in head and neck squamous cell carcinoma. Ann Oncol 2012; 23: 186-192.
12. Shitara K, Muro K, Ito S, et al. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer. Cancer Epidemiol Biomarkers Prev 2010;19:1311-1319.
13. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21: 1556-1561.
14. D'Angelo V, Ramaglia M, Iannotta A, et al. Inf uence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate. Leuk Lymphoma 2013; 54: 2639-2644.
15. Kantar M, Kosova B, Cetingul N, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:912-917.
16. Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicity in acute lymphoblastic leukemia: a meta-analysis. Tumor Biol 2012;33:1445-1454.
17. de Benoist B. Conclusions of a WHO Technical Consultation on folate and vitamin B12 defciencies. Food Nutr Bull 2008; 29(2 Suppl.):S238-S244.
18. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE). Ver. 4.03. Bethesda, MD: NCI; 2010.
19. Kumar N, Shekhar C, Kumar P, et al. Kuppuswamy's socioeconomic status scale-updating for 2007. Indian J Pediatr 2007; 74:1131-1132.
20. Borsi JD, Wesenberg F, Stokland T, et al. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia. Eur J Cancer 1991;27:1006-1009.
21. Graham ML, Shuster JJ, Kamen BA, et al. Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol 1992;31:217-222.
22. Taneja S, Bhandari N, Strand TA, et al. Cobalamin and folate status in infants and young children in a low-to-middle income community in India. Am J Clin Nutr 2007;86:1302-1309.
23. Krishnaswamy K, Madhavan Nair K. Importance of folate in human nutrition. Br J Nutr 2001; 85(Suppl. 2): S115-S124.
24. Moody K, Charlson ME, Finlay J. The neutropenic diet: what's the evidence? J Pediatr Hematol Oncol 2002;24:717-721.
25. Lindenbaum J, Allen RH. Clinical spectrum and diagnosis of folate def ciency. In: Bailey LB, editor. Folate in health and disease. New York: Marcel Dekker; 1995.
26. Bostrom BC, Erdmann GR, Kamen BA. Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol 2003;25:114-117.
27. Stover PJ. One-carbon metabolism-genome interactions in folate-associated pathologies. J Nutr 2009;139:2402-2405.
28. Jacques PF, Choumenkovitch SF. Mild MTHFR def ciency and folate status. In: MTHFR polymorphisms and disease. Georgetown, TX: Landes Bioscience; 2005. pp 54-70.
29. Lucock MD. Synergy of genes and nutrients: the case of homocysteine. Curr Opin Clin Nutr Metab Care 2006;9:748-756.
30. Liu SG, Li ZG, Cui L, et al. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma 2011;52:1030-1040.
31. D'Angelo V, Ramaglia M, Iannotta A et al. Inf uence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate. Leuk Lymphoma 2013; 54: 2639-2644.
32. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. Asystematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J 2013; 13: 498-506.
33. Lennard L, Lilleyman JS, Maddocks JL. The Effect of folate supplements on 6-mercaptopurine remission maintenance therapy in childhood leukemia. Br J Cancer 1986;53:115-119.
34. Schrøder H, Clausen N, Ostergård E, et al. Folic acid supplements in vitamin tablets: a determinant of hematological drug tolerance in maintenance therapy of childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986;3:241-247.